Atherosclerotic cardiovascular disease (ASCVD) is a leading cause of mortality worldwide. Dysregulation of glucose metabolism and inflammation are key factors in the development of atherosclerosis. The glucose-to-lymphocyte ratio (GLR) is a comprehensive marker for assessing glucose metabolism and inflammation. This study aims to evaluate the association between GLR and all-cause as well as cardiovascular disease (CVD) mortality in patients with ASCVD within the U.S. population. This retrospective cohort study recruited 1,753 ASCVD patients from the 2003–2018 National Health and Nutrition Examination Survey (NHANES) with a median follow-up of 6.25 years. Mortality outcomes were determined by linkage to the National Death Index (NDI) records up to December 31, 2019. Weighted Cox proportional hazard models were used to assess the independent association between GLR and mortality risk. Restricted cubic spline (RCS) curves were used to display the relationship between GLR and all-cause mortality visually, and two-segment Cox proportional hazards models were constructed on either side of the inflection points. Kaplan-Meier survival curves were further used to assess the relationship between GLR and mortality, and further subgroup analyses were performed. Receiver operating characteristic curve (ROC) analysis was conducted to assess the predictive ability of GLR for survival. During a median follow-up of 6.25 years, 624 deaths from various causes were observed, with 254 deaths from CVD. Cox regression analysis revealed a positive association between GLR and both all-cause and CVD mortality. Based on RCS, a J-shaped nonlinear relationship was observed between GLR and all-cause mortality in ASCVD patients, with an inflection point at 3.13. When the GLR < 3.13, it showed a significant negative association with all-cause mortality (HR 0.65, 95% CI 0.47–0.89). When GLR ≥ 3.13 for all-cause mortality, there was a significant positive correlation with all-cause mortality (HR 1.13, 95% CI 1.09–1.17). Subgroup analysis revealed a positive association between GLR and CVD mortality across most subgroups, but the correlation between GLR and CVD mortality was weaker compared to its association with all-cause mortality. In addition, an interaction was detected between GLR and age in relation to all-cause mortality. Moreover, the predictive performance of GLR on all-cause and CVD mortality seemed superior to that of glucose or lymphocytes. Our findings indicate that elevated GLR was closely associated with an increased risk of all-cause mortality and CVD mortality in ASCVD patients. Notably, the relationship between GLR and all-cause mortality exhibited a J-shaped nonlinear pattern, with an inflection point at 3.13.
Stroke is the second leading cause of death globally. Oxidative stress plays a critical role in the development of stroke. The Oxidative Balance Score (OBS) is a tool used to assess the combined impact of diet and lifestyle on the body’s antioxidant capacity. The study included stroke survivors from the National Health and Nutrition Examination Survey (1999–2018), with a total of 1,781 participants and a median follow-up duration of 6.5 years, during which 786 participants (39.59%) died. The relationship between OBS and all-cause mortality was assessed using the Cox proportional hazards model. The results indicated that individuals in higher OBS quartiles had lower mortality rates. Specifically, patients in the fourth quartile had a 41% reduced risk of all-cause mortality compared to those in the first quartile (HR = 0.59, 95% CI = 0.42–0.84, p = 0.003). Restricted cubic spline analysis revealed a linear inverse relationship between OBS and all-cause mortality. Subgroup analysis further demonstrated that the inverse association persisted across various population subgroups. Overall, our study suggests that higher levels of OBS can reduce the risk of all-cause mortality in stroke survivors and provides new evidence for their diet and lifestyle.
Background: The Composite Dietary Antioxidant Index (CDAI) is a novel and comprehensive metric for evaluating overall antioxidant capacity. However, the association of the CDAI with all-cause and cardiovascular disease (CVD) mortality among stroke survivors remains undefined. Methods: This study included 1,376 stroke survivors from the National Health and Nutrition Examination Survey (NHANES) spanning 1999 to 2018. Mortality outcomes were ascertained via the National Death Index. We utilized multivariate Cox regression models, incorporating restricted cubic spline plots, Kaplan-Meier survival analyses, and subgroup evaluations, to examine the link between CDAI and both all-cause and CVD mortality. Results: During the mean follow-up period of 86.4 months, a total of 587 participants died. The weighted Cox regression indicated that, a one-unit rise in CDAI corresponded to a 6% decline in all-cause mortality (HR = 0.94, 95% CI = 0.91–0.98, p = 0.001) and a 9% decline in CVD mortality (HR = 0.91, 95% CI = 0.86–0.97, p = 0.002). When comparing individuals in the quartile 1 with those in quartile 4, it was found that the latter exhibited a 44% reduced risk of all-cause mortality (HR = 0.56, 95% CI = 0.41–0.76, p < 0.001) and a 62% decreased risk of mortality due to CVD (HR = 0.38, 95% CI = 0.21–0.70, p = 0.002). Conclusion: The CDAI is inversely associated with all-cause and CVD mortality among stroke survivors. Specifically, higher CDAI levels are significantly linked to reduced risks of both all-cause and CVD mortality. Clinical trial number: Not application.